Table 2 Mean or individual pharmacokinetic parameters of fluconazole in children and adults
|  | Reference | N | Country | Age (years) | Dose (mg) | Route | AUC (μg・h/mL) | t1/2 (h) | Vd (L/kg) | CL (mL/min) | CL (mL/min/kg) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Children | Sato et al. [22] | 1 | Japan | 6 | 3a | IV | 91.5 | 11.9 | 0.42 | NA | NA | |
Lee et al. [24] | 24 | USA | 5–15 | 2-8a | IV | 76-201 | 17.4 | 0.86 | 21.4 | NA | ||
Seay et al. [25] | 10 | USA | 1.8–15.9 | 3-6a | IV/PO | NA | 15.6 | 0.77 | 16.8 | 0.63 | ||
Fujii et al. [20] | 17 | Japan | 0.3–18.3 | 3-12a | IV/PO | 95.0-200.9 | 17.3–23.5 | 0.49–0.69 | NA | NA | ||
Nahata et al. [26] | 8 | USA | 6–13 | 2-8a | PO | 84.9-684.3 | 19.8–42.3 | NA | NA | NA | ||
Adults | Healthy volunteers | Shiba et al. [27] | 8 | Japan | 20–22 | 25–100 | IV/PO | 19.2–86.9 | 28.6–33.4 | 41.3–59.4b | NA | NA |
Ripa et al. [28] | 18 | Italy | 20–37 | 50–150 | IV/PO | 39.8–114.2 | 29.7–32.2 | 50.9–53.4b | 20.6–21.0 | NA | ||
Takebe et al. [29] | 10 | Japan | 23–34 | 200 | PO | 253.1 | 44.7 | 49.9b | NA | NA | ||
Humphrey et al. [30] | 4 | UK | 18–45 | 1a | PO | NA | 22 | 0.7 | NA | 0.40 | ||
Thorpe et al. [31] | 14 | UK | 21–29 | 100 | PO | 93.0 | NA | NA | NA | NA | ||
Toon et al. [32] | 5 | UK | 22–66 | 50 | PO | NA | 31.2 | 0.91 | 23.8 | NA | ||
Jovanovic et al. [33] | 24 | Serbia | 22–48 | 150 | PO | 107.0 | 35.1 | NA | NA | NA | ||
Yeates et al. [34] | 10 | Germany | 27 | 100 | IV | NA | 35.0 | 0.94 | 23.0 | NA | ||
Tett et al. [35] | 10 | Australia | 18–45 | 50–400 | IV | NA | 31–46 | 42-78b | 14.8–26.2 | NA | ||
AIDS Patients | Yeates et al. [34] | 10 | Germany | 35 | 100 | IV | NA | 37.0 | 0.84 | 17.0 | NA | |
Tett et al. [35] | 11 | Australia | 25–50 | 50–400 | IV | NA | 25–69 | 31-56b | 8.8–19.8 | NA | ||
DeMuria et al. [36] | 10 | USA | 29–38 | 100 | IV | 67.2–188 | 21.8–75.2 | 35.8–59.9b | 8.9–24.8 | NA | ||
Chin et al. [37] | 1 | Canada | 37 | 400 | IV | NA | 34.2 | 28.1b | 9.5 | 0.19 | ||
Vaginal candidiasis | Houang et al. [38] | 9 | UK | 23–41 | 150 | PO | NA | 30.2 | 0.84 | NA | 0.32 | |
Burn patients | Boucher et al. [39] | 8 | USA | 24–65 | 400 | IV | 152–276 | 14.4–38.4 | 0.48–0.96 | NA | 0.19–0.53 | |